Table 1.
Summary of Patient Baseline Characteristics in the Pooled ASCEND, CAPACITY, and INSPIRE Population by Monocyte Count
| All Patients (n = 2,067) | Patients, by Monocyte Count |
|||
|---|---|---|---|---|
| <0.60 × 109 cells/L (n = 1,609) | 0.60 to <0.95 × 109 cells/L (n = 408) | ≥0.95 × 109 cells/L (n = 50) | ||
| Age, mean (SD), yr | 66.7 (7.6) | 66.4 (7.7) | 67.8 (7.3) | 67.7 (8.1) |
| Sex, n (%) | ||||
| M | 1,508 (73.0) | 1,136 (70.6) | 328 (80.4) | 44 (88.0) |
| Monocytes, × 109 cells/L | ||||
| Mean* (SD) | 0.49 (0.18) | 0.41 (0.10) | 0.71 (0.09) | 1.14 (0.29) |
| Quintile, minimum–maximum | ||||
| First | 0.10−0.34 | 0.10−0.32 | 0.60−0.62 | 0.95−0.96 |
| Second | 0.35−0.42 | 0.33−0.38 | 0.63−0.66 | 0.97−1.01 |
| Third | 0.43−0.50 | 0.39−0.44 | 0.67−0.71 | 1.02−1.09 |
| Fourth | 0.51−0.61 | 0.45−0.51 | 0.72−0.77 | 1.11−1.21 |
| Fifth | 0.62−2.81 | 0.52−0.59 | 0.78−0.94 | 1.24−2.81 |
| FVC% predicted, mean (SD) | 69.0 (15.0) | 69.7 (15.1) | 67.4 (14.3) | 63.1 (14.3) |
| DlCO% predicted, mean (SD) | 43.6 (11.4) | 44.1 (11.4) | 41.9 (11.2) | 41.4 (9.4) |
| 6MWD, mean (SD), m | 382.0 (120.6) | 385.3 (120.5) | 374.7 (119.6) | 336.3 (122.8) |
| UCSD-SOBQ total score, mean (SD) | 39.1 (24.6) | 38.6 (24.4) | 39.7 (24.9) | 47.0 (26.8) |
| Comorbidities,†n (%) | ||||
| GERD | 645 (31.2) | 473 (29.4) | 154 (37.7) | 18 (36.0) |
| CAD | 444 (21.5) | 310 (19.3) | 111 (27.2) | 23 (46.0) |
| COPD | 114 (5.5) | 83 (5.2) | 30 (7.4) | 1 (2.0) |
| MI | 111 (5.4) | 73 (4.5) | 34 (8.3) | 4 (8.0) |
| Pulmonary hypertension | 50 (2.4) | 27 (1.7) | 22 (5.4) | 1 (2.0) |
| DVT | 48 (2.3) | 39 (2.4) | 8 (2.0) | 1 (2.0) |
| CV risk factors, n (%) | ||||
| Smoker‡ | 1,372 (66.4) | 1,064 (66.1) | 276 (67.6) | 32 (64.0) |
| Hypertension | 1,068 (51.7) | 815 (50.7) | 230 (56.4) | 23 (46.0) |
| Obesity§ | 897 (43.4) | 686 (42.6) | 187 (45.8) | 24 (48.0) |
| Hypercholesterolemia | 864 (41.8) | 650 (40.4) | 190 (46.6) | 24 (48.0) |
| Diabetes | 454 (22.0) | 348 (21.6) | 95 (23.3) | 11 (22.0) |
| Chronic immunosuppressant use,ǁn (%) | ||||
| Steroid (systemic) | 135 (6.5) | 102 (6.3) | 24 (5.9) | 9 (18.0) |
| Nonsteroid | 33 (1.6) | 25 (1.6) | 7 (1.7) | 1 (2.0) |
| Neither | 1,918 (92.8) | 1,496 (93.0) | 382 (93.6) | 40 (80.0) |
Definitionof abbreviations: 6MWD = 6-minute-walk distance; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; CV = cardiovascular; DVT = deep vein thrombosis; GERD = gastroesophageal reflux disease; MI = myocardial infarction; UCSD-SOBQ = University of California, San Diego, Shortness of Breath Questionnaire.
At time of event (idiopathic pulmonary fibrosis progression, defined as ≥10% absolute decline in FVC% predicted, ≥50 m decline in 6MWD, or death) or censor.
Includes comorbidities reported in >2% of the total patient population.
Current/former.
Body mass index >30 kg/m2.
At any time from baseline through to end of 1-year follow-up period; values may sum more than 100%.